Progress Is Being Made Toward Improvements in Biomarker Testing, Turnaround Times for NSCLCOctober 26th 2021
In an interview with Targeted Therapies in Oncology, Nicholas J. Robert, MD, discussed what the results to date of the MYLUNG study mean for patients with non–small cell lung cancer.
Pursuing Optimal Therapy Remains a Challenge in Indolent B-Cell LymphomaOctober 25th 2021
A significant proportion of patients worldwide live disease-free for a decade or longer following first-line therapy, with various approaches suggesting that there may be pathways to develop approaches for a cure for at least a subset of patients
High pCR Rate Shows Potential for Neoadjuvant Osimertinib in EGFR+ NSCLCOctober 24th 2021
Neoadjuvant osimertinib may lead to a better mechanistic understanding of what drives incomplete response and residual disease for patients with EGFR-mutant NSCLC. according to Collin M. Blakely, MD, PhD.
Further Analyses Expand Upon Duration of Benefit With Sotorasib in KRAS G12C+ NSCLCOctober 23rd 2021
Following the FDA approval of sotorasib for the treatment of KRAS G12C-positive non–small cell lung cancer, there is a great deal of interest in the KRAS inhibitor and its potential benefit.
Convenient Clinical Trial Locations, Research Staff Availability Mitigate Barriers to Trial Access, Survey SaysOctober 23rd 2021
Flexible patient-focused approaches may increase clinical trial accessibility and enrollment in international lung cancer clinical trials beyond the COVID-19 pandemic.
Although Safe and Tolerable, Lurbinectedin/Doxorubicin Combo Misses Efficacy Mark in SCLC Addition of Atezolizumab to NeoadjuvantOctober 21st 2021
Small cell lung cancer is the most aggressive form of lung cancer and mostly occurs in smokers. Although the disease has proved to be sensitive to chemotherapy and radiation, responses are short and those who relapse have short survival.
Doctors Debate: Should Maintenance Therapy Be Included in the Treatment of Acute Myeloid Leukemia?October 20th 2021
Despite the success of implementing maintenance therapy in other leukemias, the key challenge with administering maintenance therapy in acute myeloid leukemia has been identifying an effective drug.
New Mechanisms Under Study to Overcome Osimertinib Resistance in EGFR+ NSCLCOctober 18th 2021
Although osimertinib has been shown to overcome T790M-mediated mutations in the second-line setting, as with other EGFR tyrosine kinase inhibiors progression on osimertinib is inevitable.